Antibiotic-resistant GBS strains may explain newborn infections

Every year, Group B Streptococcus (GBS) screening and antibiotics during labor prevent thousands of newborn infections. Yet a stubborn subset of cases persists—babies who develop life-threatening pneumonia, meningitis, or sepsis despite their mothers receiving treatment. Now, a Michigan State University study published in Nature Microbiology offers a potential explanation: mutant GBS strains that survive antibiotic exposure in the birth canal.

The research team analyzed postpartum GBS samples and identified strains with genetic mutations conferring resistance to standard intrapartum antibiotics like penicillin. These variants, the study confirms, can colonize the birth canal undetected by routine prenatal screens and infect newborns during delivery. "This isn’t about treatment failure in the traditional sense," explains lead author Dr. Adam Waickman, "but about strains that have evolved to exploit a temporary window when antibiotics are present but not yet fully effective."

The clinical implications are immediate—but the solutions are not. Current CDC guidelines recommend universal late-pregnancy screening and antibiotic prophylaxis for GBS-positive mothers, a protocol that remains unchanged by these findings. What the study does reveal is a critical gap: prenatal screening may miss these resistant strains, which appear to emerge after the standard 35–37 week test.

The study’s design carries important limitations. With a sample size focused on postpartum isolates from a single regional hospital, the findings don’t yet establish how widespread these mutant strains are. "We’ve shown how this can happen," notes Waickman, "but not how often—that’s the next question." The team also emphasizes that this isn’t a failure of antibiotics themselves, but of timing: the mutations arise in response to the brief, high-dose exposure during labor, not from chronic overuse.

For patients, the message is clear: nothing changes today. Pregnant women should still follow existing GBS screening and prophylaxis protocols, which remain highly effective against the majority of strains. The study’s value lies in its potential to refine future guidelines—perhaps by adjusting screening timing or adding resistance monitoring for high-risk cases.

What’s missing? Longitudinal data tracking whether these strains persist in mothers or recur in subsequent pregnancies, and whether alternative antibiotics (like clindamycin) could close the gap. Regulatory bodies haven’t weighed in, but the findings will likely prompt calls for updated surveillance protocols in neonatal units.

The discovery also raises a broader question: Are we seeing the early stages of GBS adapting to prophylaxis, much like Staphylococcus aureus did with methicillin? "That’s the scenario we’re watching for," says Waickman, "but we’re not there yet."